US 11,999,993 B2
Use of biomarkers in identifying cancer patients that will be responsive to treatment with a PRMT5 inhibitor
Dirk Brehmer, Freiburg (DE); Lijs Beke, Antwerp (BE); Dana Suzanne Gaffney, Green Lane, PA (US); and Christopher H. Moy, Schwenksville, PA (US)
Assigned to Janssen Pharmaceutica NV, Beerse (BE)
Filed by Janssen Pharmaceutica NV, Beerse (BE)
Filed on Feb. 10, 2022, as Appl. No. 17/669,008.
Application 17/669,008 is a division of application No. 16/487,852, granted, now 11,279,970, previously published as PCT/EP2018/054644, filed on Feb. 26, 2018.
Claims priority of provisional application 62/464,006, filed on Feb. 27, 2017.
Prior Publication US 2022/0205026 A1, Jun. 30, 2022
Int. Cl. C12Q 1/6827 (2018.01); G16H 50/30 (2018.01)
CPC C12Q 1/6827 (2013.01) [G16H 50/30 (2018.01); C12Q 2600/106 (2013.01); C12Q 2600/112 (2013.01); C12Q 2600/118 (2013.01)] 8 Claims
 
1. A method of treating a non-small cell lung cancer (NSCLC) in a human patient, the method comprising:
administering a protein arginine N-methyltransferase 5 (PRMT5) inhibitor to the human patient, wherein the human patient has been determined to have a I696fs mutation in RBM10 wherein the PRMT5 inhibitor is

OG Complex Work Unit Chemistry
or a pharmaceutically acceptable salt thereof or a solvate thereof.